Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEU1 | Q99519 | 16/20 | 0.82 |
| ▸ | NEU3 | Q9UQ49 | 10/20 | 0.76 |
| ▸ | NEU4 | Q8WWR8 | 4/20 | 0.73 |
| ▸ | NEU2 | Q9Y3R4 | 3/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21164717 | 1.00 | NEU1 (0.82) | NEU1NEU3NEU4NEU2 | |
| SCHEMBL21164716 | 0.90 | NEU1 (1.00) | NEU1NEU3NEU4NEU2 | |
| SCHEMBL14933699 | 0.90 | NEU1 (1.00) | NEU1NEU3NEU4NEU2 | |
| SCHEMBL22111467 | 0.90 | NEU1 (1.00) | NEU1NEU3NEU4NEU2 | |
| SCHEMBL22276975 | 0.86 | NEU3 (1.00) | NEU1NEU3NEU4NEU2 | |
| SCHEMBL14933700 | 0.86 | NEU3 (1.00) | NEU1NEU3NEU4NEU2 | |
| SCHEMBL21164804 | 0.86 | NEU3 (1.00) | NEU1NEU3NEU4NEU2 | |
| SCHEMBL16544470 | 0.84 | NEU1 (0.57) | NEU1NEU3NEU4NEU2 | |
| SCHEMBL22276971 | 0.84 | NEU1 (1.00) | NEU1NEU3NEU4NEU2 | |
| SCHEMBL22276977 | 0.84 | NEU1 (1.00) | NEU1NEU3NEU4NEU2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150064282-A1 | USE OF NEU1 SIALIDASE INHIBITORS IN THE TREATMENT OF CANCER | SZEWCZUK, MYRON R. (CA) | 2015-03-05 | — | — | US | disclosed |
| WO-2013063679-A9 | USE OF NEU1 SIALIDASE INHIBITORS IN THE TREATMENT OF CANCER | JOSEFOWITZ PAUL ZACHARY (GB) | 2013-07-11 | — | — | WO | disclosed |
| WO-2013063679-A1 | USE OF NEUL SIALIDASE INHIBITORS IN THE TREATMENT OF CANCER | JOSEFOWITZ PAUL ZACHARY (GB) | 2013-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150064282-A1 | USE OF NEU1 SIALIDASE INHIBITORS IN THE TREATMENT OF CANCER | NEU1, NEU2, NEU3 | NEU1 1/4885NEU3 3/4885NEU4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.